Rexigo contains relugolix, an oral medication used to manage hormone-sensitive conditions, particularly in men with advanced prostate cancer. Unlike traditional injectable therapies, Rexigo offers a convenient tablet form that lowers testosterone levels effectively, which is important for slowing the progression of certain hormone-driven cancers.

Mechanism of Action
Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist. It works by blocking the GnRH receptors in the pituitary gland. This prevents the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn reduces the production of testosterone in men. Since testosterone fuels the growth of many prostate cancers, reducing its levels helps control disease progression. Unlike agonists that cause an initial hormone surge, relugolix leads to a rapid decrease in testosterone without the temporary spike.

Uses
Rexigo is primarily used in adult men for:

• Advanced or metastatic prostate cancer that is sensitive to hormone suppression

Adverse Effects
Some commonly reported side effects include:

• Hot flashes

• Fatigue

• Diarrhea

• Increased blood sugar or cholesterol levels

• Muscle or joint pain